Stirling wins patent for equine heaves treatment

Stirling presents results of Loma salmonae treatment trials

Stirling wins distribution rights to PetQuench

Starpharma has released positive results from VivaGel clinical trial.

The CSIRO is sponsoring a session on biomaterials and regenerative medicine at BIO2007. Kate McDonald spoke to CSIRO's theme leader for the area, Keith McLean, about this competitive but challenging field.

A study conducted for Perth-based Stirling Products (ASX:STI) has shown that its beta agonist ST810 reduced weight gain in obese Zucker rats.

The privately funded Australian Cancer Research Foundation (ACRF) has awarded a grant of AUD$900,000 to Melbourne's St Vincent's Institute (SVI) to establish a rational drug discovery facility for cancer research.

Stirling Products' (ASX:STI) second study into the effects of its lead beta agonist growth promotion product ST810 in broiler chickens has shown positive preliminary results, according to the company.

Stirling Products (ASX:STI) will extend its proof-of-concept studies to include a more direct delivery method after analysis of levels of its beta agonist ST810, a single enantiomer form of salbutamol, in the bloodstream of merino lambs showed that the growth promoter was not getting into the bloodstream.

Stirling Products (ASX:STI) has reported that its ST810 beta agonist has produced a 16 per cent improvement in weight gain in a 28-day US trial in 196 pigs.

Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.